贵州百灵：糖宁通络片临床试验申请获批准

Core Viewpoint - Guizhou Bailing (002424.SZ) announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the clinical trial of Tangning Tongluo tablets, which are intended for the treatment of type 2 diabetes [1] Group 1 - The clinical trial approval is a significant milestone for the company, indicating progress in its pharmaceutical development pipeline [1] - The approved clinical trial will focus on the efficacy and safety of Tangning Tongluo tablets in patients with type 2 diabetes [1] - This development may enhance the company's position in the diabetes treatment market, which is experiencing growing demand [1]